Inhibitor Therapeutics INTI
OTC INTI
$0.10 +0.00 (+0.00%)
At close: Oct 1, 2026 · 4:00 PM EDT

Inhibitor Therapeutics (INTI) Price to Earnings (2022 - 2023)

Updated

Inhibitor Therapeutics' Price to Earnings came in at 0.82 for Q3 2023, up 31.5% from the prior quarter.

Analysis

Inhibitor Therapeutics (INTI) Price to Earnings (2022 - 2023) Analysis & Trends

For FY2022, Inhibitor Therapeutics' Price to Earnings was 3.07.

  • The five-year range for quarterly Price to Earnings is 0.63 (Q2 2023) to 3.07 (Q4 2022).
  • Business Quant data shows INTI's Price to Earnings at 0.63 (Q2 2023), 0.89 (Q1 2023) and 3.07 (Q4 2022) in the three quarters before Q3 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Inhibitor Therapeutics 17.38 Mn 17.38 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 0.82
Jun 30, 2023 0.63
Mar 31, 2023 0.89
Dec 31, 2022 3.07
API Access

Inhibitor Therapeutics Price to Earnings API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-earnings&ticker=INTI&period=max&api_key=YOUR_API_KEY